ss

Radical innovation consists of research and development of new assets, whether they are synthetic, herbal medicines, biological, nutraceuticals, or dermocosmetics products. This research line requires a high investment cost and a long research period.

The company has been engaged in radical innovation research for more than 10 years, when it initially opted for phytomedicines and, today, continues to reinforce the importance of the subject by treating it as one of the cornerstones of its Strategic Planning.

All our actions converge on Aché’s goal to become the innovation leader among national pharmaceutical companies and to achieve a global reach.

Created to develop innovative therapeutic solutions for unmet medical needs and to support established processes for renewing and maintaining drug records, the Molecular Design and Synthesis Laboratory (LDSM) was expanded at the Guarulhos plant in 2019. In this laboratory, 1,500 molecules have already been designed, 500 of which were synthesized internally and another 1,000 by external partners, for the different projects of the Company, contributing to the inventive advance and scientific production of global relevance in the Brazilian pharmaceutical industry. The expansion of the laboratory reaffirms Aché's commitment to innovation, in addition to fully meeting regulatory demands for the defense of our portfolio and pipeline. Created to develop innovative therapeutic solutions for unmet medical needs and to support the established processes of renovation and maintenance of drug registrations, the Molecular Design and Synthesis Laboratory (LDSM) was expanded at the Guarulhos plant in 2019. In this laboratory, 1,500 molecules have already been designed, 500 of which were synthesized internally and another 1,000 by external partners, for the different projects of the Company, contributing to the inventive advance and scientific production of global relevance in the Brazilian pharmaceutical industry. The expansion of the laboratory reaffirms Aché's commitment to innovation, in addition to fully meeting regulatory demands for the defense of our portfolio and pipeline.

The release of this laboratory enabled Aché, in 2016, to enter the Structural Genomics Consortium (SGC), an international partnership between universities, governments, and pharmaceutical industries to speed up the development of new medicines. The first result is the partnership between Aché, another national pharmaceutical company and Unicamp for the feasibility of an unprecedented research program aimed at the development of new oncological and anti-infectious drugs. For the first time in Brazil, the research will be based on the open innovation model, that is, all the knowledge generated (up to the phase of validating the therapeutic potential of biological targets) will be in the public domain.

In December 2017, the Brazilian Biodiversity Prospecting Program was created, made possible thanks to the partnership between Aché, the National Biosciences Laboratory (LNBio) and Phytobios, a company that conducts expeditions to different biomes for the collection of samples and operates in the prototype development. LNBio is part of the National Center for Research in Energy and Materials (CNPEM), a social organization supervised by the Ministry of Science, Technology, Innovations and Communications (MCTIC).

In the company, innovation is essential and present not only in products and services, but in its broadest form, undergoing our processes, reaching the routine of each employee.